Loading…
KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer
The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prog...
Saved in:
Published in: | Journal of Cancer 2024-01, Vol.15 (10), p.3140-3150 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 3150 |
container_issue | 10 |
container_start_page | 3140 |
container_title | Journal of Cancer |
container_volume | 15 |
creator | Han, Zhihang Song, Chuanjun Li, Dongqing Zhu, Weiyou Sun, Jiukang Yao, Jialing Gan, Wenyuan Wang, Fufeng Yang, Xiaodong Zhu, Lingjun |
description | The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with
and
mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P < 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the
signaling network were also significantly associated with shortened PFS (univariate, P < 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02).
mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches. |
doi_str_mv | 10.7150/jca.94410 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11064249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3051427934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-ad30809d173d222bdd17c9d2198538b55a7779d24ebb143c51d24cb0b9622bb23</originalsourceid><addsrcrecordid>eNpVkU9PHSEUxUnTphrrol_AsLSLsfybYVgZ86LV1IlG7ZrcAd4TMw8UGBM_QL93seqLsuHccH7nkhyEvlNyIGlLft4ZOFBCUPIJbdOey0Z1nfj8Tm-h3ZzvSD1cMSn4V7TFe0k6Rftt9Pf3cMOO8DAXKD6GjCFYfOpXt_gyuUeYXDAOxyW2w3DVQM7ReCjObgCY8LVfBShzchXOFYurEHPxBp8F6w2UmDL2AQ-uQH6GDF7EKSZnSoUXUBekb-jLEqbsdl_vHfTn5PhmcdqcX_w6WxydN4bzrjRgOemJslRyyxgbbVVGWUZV3_J-bFuQUtZZuHGkgpuWVm1GMqquukfGd9DhS-79PK6dNS6UBJO-T34N6UlH8PrjS_C3ehUfNaWkE0yomrD_mpDiw-xy0WufjZsmCC7OWXPSUsGk4qJaf7xYTYo5J7fc7KFEP1ena3X6f3XVu_f-YxvnW1H8HyLFlhI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3051427934</pqid></control><display><type>article</type><title>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Han, Zhihang ; Song, Chuanjun ; Li, Dongqing ; Zhu, Weiyou ; Sun, Jiukang ; Yao, Jialing ; Gan, Wenyuan ; Wang, Fufeng ; Yang, Xiaodong ; Zhu, Lingjun</creator><creatorcontrib>Han, Zhihang ; Song, Chuanjun ; Li, Dongqing ; Zhu, Weiyou ; Sun, Jiukang ; Yao, Jialing ; Gan, Wenyuan ; Wang, Fufeng ; Yang, Xiaodong ; Zhu, Lingjun</creatorcontrib><description>The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with
and
mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P < 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the
signaling network were also significantly associated with shortened PFS (univariate, P < 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02).
mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.94410</identifier><identifier>PMID: 38706918</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Journal of Cancer, 2024-01, Vol.15 (10), p.3140-3150</ispartof><rights>The author(s).</rights><rights>The author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11064249/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11064249/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,36990,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38706918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Zhihang</creatorcontrib><creatorcontrib>Song, Chuanjun</creatorcontrib><creatorcontrib>Li, Dongqing</creatorcontrib><creatorcontrib>Zhu, Weiyou</creatorcontrib><creatorcontrib>Sun, Jiukang</creatorcontrib><creatorcontrib>Yao, Jialing</creatorcontrib><creatorcontrib>Gan, Wenyuan</creatorcontrib><creatorcontrib>Wang, Fufeng</creatorcontrib><creatorcontrib>Yang, Xiaodong</creatorcontrib><creatorcontrib>Zhu, Lingjun</creatorcontrib><title>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with
and
mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P < 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the
signaling network were also significantly associated with shortened PFS (univariate, P < 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02).
mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.</description><subject>Research Paper</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkU9PHSEUxUnTphrrol_AsLSLsfybYVgZ86LV1IlG7ZrcAd4TMw8UGBM_QL93seqLsuHccH7nkhyEvlNyIGlLft4ZOFBCUPIJbdOey0Z1nfj8Tm-h3ZzvSD1cMSn4V7TFe0k6Rftt9Pf3cMOO8DAXKD6GjCFYfOpXt_gyuUeYXDAOxyW2w3DVQM7ReCjObgCY8LVfBShzchXOFYurEHPxBp8F6w2UmDL2AQ-uQH6GDF7EKSZnSoUXUBekb-jLEqbsdl_vHfTn5PhmcdqcX_w6WxydN4bzrjRgOemJslRyyxgbbVVGWUZV3_J-bFuQUtZZuHGkgpuWVm1GMqquukfGd9DhS-79PK6dNS6UBJO-T34N6UlH8PrjS_C3ehUfNaWkE0yomrD_mpDiw-xy0WufjZsmCC7OWXPSUsGk4qJaf7xYTYo5J7fc7KFEP1ena3X6f3XVu_f-YxvnW1H8HyLFlhI</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Han, Zhihang</creator><creator>Song, Chuanjun</creator><creator>Li, Dongqing</creator><creator>Zhu, Weiyou</creator><creator>Sun, Jiukang</creator><creator>Yao, Jialing</creator><creator>Gan, Wenyuan</creator><creator>Wang, Fufeng</creator><creator>Yang, Xiaodong</creator><creator>Zhu, Lingjun</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</title><author>Han, Zhihang ; Song, Chuanjun ; Li, Dongqing ; Zhu, Weiyou ; Sun, Jiukang ; Yao, Jialing ; Gan, Wenyuan ; Wang, Fufeng ; Yang, Xiaodong ; Zhu, Lingjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-ad30809d173d222bdd17c9d2198538b55a7779d24ebb143c51d24cb0b9622bb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Zhihang</creatorcontrib><creatorcontrib>Song, Chuanjun</creatorcontrib><creatorcontrib>Li, Dongqing</creatorcontrib><creatorcontrib>Zhu, Weiyou</creatorcontrib><creatorcontrib>Sun, Jiukang</creatorcontrib><creatorcontrib>Yao, Jialing</creatorcontrib><creatorcontrib>Gan, Wenyuan</creatorcontrib><creatorcontrib>Wang, Fufeng</creatorcontrib><creatorcontrib>Yang, Xiaodong</creatorcontrib><creatorcontrib>Zhu, Lingjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Zhihang</au><au>Song, Chuanjun</au><au>Li, Dongqing</au><au>Zhu, Weiyou</au><au>Sun, Jiukang</au><au>Yao, Jialing</au><au>Gan, Wenyuan</au><au>Wang, Fufeng</au><au>Yang, Xiaodong</au><au>Zhu, Lingjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>15</volume><issue>10</issue><spage>3140</spage><epage>3150</epage><pages>3140-3150</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo similar treatment regimens, notable disparities in their prognostic outcomes can be observed. Therefore, tissue and plasma samples from 40 mCRC patients underwent next-generation sequencing targeting 425 cancer-relevant genes. Genomic variations and canonical oncogenic pathways were investigated for their prognostic effects in association with progression-free survival (PFS) of these patients. We found that patients with
and
mutations exhibited worse prognostic outcomes after chemotherapy-based treatment (univariate, P < 0.01). Further pathway analysis indicated that alterations in the homologous recombination pathway and in the
signaling network were also significantly associated with shortened PFS (univariate, P < 0.01). Additionally, mutation signature analysis showed that patients with higher proportions of defective mismatch repair (dMMR)-related mutational signatures. Had a worse prognosis (univariate, P = 0.02).
mutations (hazard ratio [HR], 4.47; 95% confidence interval [CI], 1-19.93; P =0.050) and dMMR signature proportions (HR, 3.57; 95% CI, 1.42-8.96; P = 0.007) remained independently associated with PFS after multivariate analysis and the results were further externally validated. These findings may enhance our understanding of this disease and may potentially facilitate the optimization of its treatment approaches.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>38706918</pmid><doi>10.7150/jca.94410</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1837-9664 |
ispartof | Journal of Cancer, 2024-01, Vol.15 (10), p.3140-3150 |
issn | 1837-9664 1837-9664 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11064249 |
source | PubMed (Medline); Publicly Available Content (ProQuest) |
subjects | Research Paper |
title | KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A06%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KMT2A%20Mutations%20and%20High%20Prevalence%20of%20dMMR-associated%20Mutational%20Signatures%20as%20Prognostic%20Indicators%20in%20Metastatic%20Colorectal%20Cancer&rft.jtitle=Journal%20of%20Cancer&rft.au=Han,%20Zhihang&rft.date=2024-01-01&rft.volume=15&rft.issue=10&rft.spage=3140&rft.epage=3150&rft.pages=3140-3150&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.94410&rft_dat=%3Cproquest_pubme%3E3051427934%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c336t-ad30809d173d222bdd17c9d2198538b55a7779d24ebb143c51d24cb0b9622bb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3051427934&rft_id=info:pmid/38706918&rfr_iscdi=true |